Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8236 to 8250 of 9009 results

  1. Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]

    Discontinued Reference number: GID-TA10464

  2. Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612]

    Discontinued Reference number: GID-TA10484

  3. Avelumab for maintenance treatment of advanced gastric or gastro-oesophageal junction cancer after platinum-based chemotherapy [ID2693]

    Discontinued Reference number: GID-TA10628

  4. Crizotinib for treating metastatic c-MET exon 14-positive non-small-cell lung cancer [ID1472]

    Discontinued Reference number: GID-TA10625

  5. Nivolumab for treating platinum-resistant advanced or recurrent ovarian cancer [ID2714]

    Discontinued Reference number: GID-TA10590

  6. Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]

    Discontinued Reference number: GID-TA10490

  7. Masitinib for treating amyotrophic lateral sclerosis [ID967]

    Discontinued Reference number: GID-TA10157

  8. Idelalisib with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia [ID839]

    Discontinued Reference number: GID-TA10109

  9. Housing: planning to improve health and wellbeing

    Discontinued Reference number: GID-NG10053

  10. Lower urinary tract symptoms in men, trans and non-binary people with a prostate: assessment and management (update)

    Discontinued Reference number: GID-NG10300

  11. Epiduroscopic lumbar discectomy via the sacral hiatus for sciatica

    Discontinued Reference number: GID-IP2806

  12. Terevalefim for treating delayed graft function after kidney transplant [ID1490]

    Discontinued Reference number: GID-TA11098

  13. Nivolumab with ipilimumab for untreated PD-L1 positive unresectable or metastatic urothelial cancer [ID3829]

    Discontinued Reference number: GID-TA10707

  14. Breathlessness

    Discontinued Reference number: GID-NG10387

  15. Amcenestrant for treating ER-positive, HER2-negative advanced breast cancer after hormonal therapy [ID3919]

    Discontinued Reference number: GID-TA10803